Skip to main content

Table 4 Neuropathological characteristics of brain donors with CTE

From: Structural MRI profiles and tau correlates of atrophy in autopsy-confirmed CTE

  Brain donors with CTE (N = 55) Brain donors with CTE+ (N = 35) Brain donors with CTE only (N = 20) P-valuea
Brain weight Mean SD Mean SD Mean SD --
 Grams 1255.16 161.49 1215.60 154.66 1324.40 152.92 0.02
Semi-quantitative ratings of p-tau severity, 0–3 scale Mean SD Mean SD Mean SD --
 Dorsolateral frontal cortex 2.33 0.80 2.44 0.79 2.15 0.81 0.20
 Rolandic cortex 1.58 1.12 1.67 1.14 1.45 1.10 0.50
 Inferior frontal cortex 2.06 0.93 2.27 0.91 1.70 0.87 0.03
 Inferior parietal cortex 1.98 1.02 2.09 1.04 1.79 0.98 0.31
 Superior temporal cortex 2.31 0.91 2.44 0.86 2.10 0.97 0.19
 CA1 1.96 1.05 2.11 1.05 1.70 1.03 0.16
 CA2 1.91 1.05 1.80 1.16 2.11 0.81 0.26
 CA4 1.89 1.08 1.86 1.06 1.95 1.15 0.76
 Entorhinal 2.37 0.88 2.35 0.95 2.40 0.75 0.85
 Amygdala 2.33 0.86 2.29 0.93 2.40 0.75 0.64
 Thalamus 1.85 1.01 1.82 1.03 1.89 0.99 0.81
 Substantia nigra 1.80 0.95 1.74 0.85 1.90 1.12 0.56
 Locus coeruleus 2.25 0.76 2.18 0.81 2.35 0.67 0.44
 Dentate nucleus 0.92 0.90 0.85 0.89 1.06 0.94 0.45
CTE stage n % n % n % 0.86
 Stage I 2 3.8 1 2.9 1 5.0
 Stage II 5 9.6 4 11.4 1 5.0
 Stage III 19 34.5 12 34.3 7 35.0
 Stage IV 29 52.7 18 51.4 11 55.0
Alzheimer’s disease n % n % n % --
 Yes 15 27.3 15 42.9 0 0
Lewy body disease n % n % n % --
 Brain stem predominant 6 10.9 6 17.1 0 0
 Limbic (transitional)/neocortical (diffuse) 11 20.0 11 31.4 0 0
Frontotemporal lobar degeneration (FTLD) n % n % n % --
 FTLD-tau 4 7.3 4 12.1 0 0
 FTLD-TDP-43 5 9.1 5 14.3 0 0
Motor neuron disease n % n % n % --
 Yes 3 5.4 3 8.6 0 0
Prion disease n % n % n % --
 Yes 2 3.6 2 5.7 0 0
CERAD neuritic plaque score n % n % n % 0.03
 No neuritic plaques 18 32.7 7 20.0 11 55.0
 Sparse neuritic plaques 26 47.3 18 51.4 8 40.0
 Moderate neuritic plaques 7 12.7 6 17.1 1 5.0
 Frequent neuritic plaques 4 7.3 4 11.4 0 0
Thal phase n % n % n % 0.02
 Phase 0 (A0) 5 9.1 4 11.4 1 5.0
 Phase 1/2 (A1) 8 14.5 2 5.7 6 30.0
 Phase 3 (A2) 11 20.0 5 14.3 6 30.0
 Phase 4/5 (A3) 31 56,4 24 68.6 7 35.0
Braak stage n % n % n % 0.02
 Stage 0 1 1.8 1 2.9 0 0
 Stage I/II 8 14.5 3 8.6 5 25.0
 Stage III/IV 27 49.1 14 40.0 13 65.0
 Stage V/VI 19 34.5 17 48.6 2 10.0
White matter rarefaction n % n % n % 0.31
 Moderate-severe 35 63.6 24 68.6 11 55.0
Arteriolosclerosis n % n % n % 0.91
 Moderate-severe 38 69.1 24 68.6 14 70.0
  1. Note. Brain donors with CTE+ included those with CTE and other neurodegenerative disease diagnoses whereas the CTE only group had CTE and no other neurodegenerative disease diagnoses. aIndependent samples t-test compared brain donors with CTE+ and CTE only on all variables for which mean and standard deviations are reported. Chi-square was used to test for group differences for all other variables. Due to missing data, sample sizes include n = 54 for dorsolateral frontal cortex, inferior parietal cortex, superior temporal cortex, CA2, and entorhinal; n = 53 for rolandic cortex, inferior frontal cortex, locus coeruleus, and thalamus; and n = 52 for dentate nucleus